Trial Profile
A 24 week, MRI based, double-blind, randomised, placebo-controlled, modified dose-escalation trial to evaluate the safety, efficacy and pharmacokinetics of BIRT 2584 XX tablets at doses of 100, 300 and 500 mg administered once daily in patients with relapsing forms of Multiple Sclerosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs BIRT 2584 XX (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 03 Apr 2022 This trial has been completed in Netherland, according to European Clinical Trials Database record.
- 05 Dec 2011 New trial record